ClinicalTrials.gg
RecruitingNCT04711915Updated Nov 18, 2026

Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans

A Phase 1 interventional study of 0.1 mg/kg Dimethyltryptamine (DMT) and 0.3 mg/kg Dimethyltryptamine (DMT) in Major Depressive Disorder and Depression, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Yale University · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 8 months later.
Updated Nov 18, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Depressive Disorder, Major by Yale University — 6 open to participants now, 8 under way, none of them phase 3. Depressive Disorder, Major · Yale University.

Planned enrollment
14th of 16
10 · median 29
Started
2021
the only one that year
Phase 1
4 of 22
2 open now
Registered
15th of 22
by date

Among the 22 studies in Depressive Disorder, Major by Yale University, this one is the 14th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2021, is one of 4 in phase 1, and was the 15th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

6 of the 22 studies in Depressive Disorder, Major by Yale University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Depressive Disorder, Major by Yale University, or all of them as a file.
02

Study summary

The goal of this fixed order, open-label, dose-escalation study is to investigate the safety and efficacy of specific doses of dimethyltryptamine (DMT) in humans.

Read the detailed description

The results of this study will inform the doses to be used in a larger, double-blind, randomized, placebo-controlled, crossover study. Since the goal of the open label study is to inform the double-blind, randomized, placebo-controlled study, the investigators are citing the hypothesis of the latter solely for providing context. The investigators hypothesize that the administration of DMT will result in neuroplastic changes in healthy and depressed subjects. These changes in neuroplasticity will be indexed using electroencephalographic (EEG) measures and tasks. These neuronal changes may in parallel cause changes in mood measured both in healthy and depressed subjects, which will be captured using appropriate psychometric measures of mood.

03

Conditions studied

  • Major Depressive Disorder
  • Depression
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Healthy controls inclusion criteria:

  • Medically healthy
  • Psychiatrically healthy

Healthy controls exclusion criteria:

  • Unstable medical conditions
  • Psychiatric illness

Depression inclusion criteria:

  • Medically healthy
  • Diagnosis of major depressive disorder

Depression exclusion criteria:

-Unstable medical conditions

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Active comparator
    0.1 mg/kg DMT

    0.1 mg/kg DMT administered intravenously

    Drug: 0.1 mg/kg Dimethyltryptamine (DMT)

  • Active comparator
    0.3 mg/kg DMT

    0.3 mg/kg DMT administered intravenously

    Drug: 0.3 mg/kg Dimethyltryptamine (DMT)

Interventions

  • Drug0.1 mg/kg Dimethyltryptamine (DMT)

    0.1 mg/kg DMT

    Also known as: Low Dose DMT

  • Drug0.3 mg/kg Dimethyltryptamine (DMT)

    0.3 mg/kg DMT

    Also known as: Moderate Dose DMT

06

What researchers measure

Primary outcomes

  1. Change in Blood Pressure

    Systolic and diastolic blood pressure will be measured before and several times after the administration of DMT on each test day.

    Time frame: -60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration

  2. Change in Heart Rate

    Heart rate will be measured before and several times after the administration of DMT on each test day.

    Time frame: -60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration

  3. Change in Psychedelic Effects

    The modified Altered States of Consciousness Rating Scale (ASC) will be used to assess drug-induced altered states of consciousness before and several times after drug administration. This is a 23-item subjective rating scale that will be completed using a visual analog scale format. Questions are scored 0 to 100 each; higher numbers indicate greater psychedelic effects.

    Time frame: -60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration

  4. Change in Anxiety

    Anxiety will be assessed using a visual analog scale that subjects will be asked to score from 0 (not at all) to 100 (worst ever) to capture the net anxiety produced by DMT. This will be collected before and several times after DMT administration.

    Time frame: -60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration

  5. Drug Reinforcing Effects

    Subjects will be asked to answer questions such as (1) How likely are you to use this drug? and (2) How much are you willing to pay for this experience? using a visual analog scale.

    Time frame: +120 minutes after DMT administration

  6. Overall Tolerability assessed by the VAS

    Overall tolerability will be assessed using a visual analog scale that subjects will be asked to score from 0 (well tolerated) to 100 (intolerable) to capture the net tolerability of DMT.

    Time frame: +120 minutes after DMT administration

07

Study locations

1 of 1 sites recruiting
  • Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine
    West Haven, Connecticut 06516, United States
    Recruiting
    • Schizophrenia Research Clinic · Contact203-932-5711
    • Deepak C D'Souza, MD · Principal investigator
08

References and documents

Publications

  • Swieczkowski D, Kwasny A, Cubala WJ. Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials. Prog Neuropsychopharmacol Biol Psychiatry. 2025 Jul 13;140:111419. doi: 10.1016/j.pnpbp.2025.111419. Epub 2025 Jun 7. PubMed 40484114 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Jul 2030, 111 months after the start.

Of 49 non-industry phase 1 interventional studies under Depressive Disorder, Major, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 16. This study's planned 111 months is above that.

Counting every sponsor, half of 89 studies reached it within 16 months; a quarter within 5 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Jul 2026 → Jul 2030 and completion Dec 2026 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2021
First posted
Jan 15, 2021
StartActual
Mar 17, 2021
Primary completionEst.
Jul 1, 2030was Jul 2026
CompletionEst.
Dec 1, 2030was Dec 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 18, 2026
Sites
Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine is now Recruiting
Nov 18, 2026
Primary completion
Jul 1, 2026→Jul 1, 2030
Nov 18, 2026
Study completion
Dec 1, 2026→Dec 1, 2030
Nov 18, 2026
Enrollment
30→10
Nov 18, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40484114 ↗
Nov 18, 2026
Contact
Study contact now listed: added h•••@yale.edu · •••5711. See the current contact
Nov 18, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine · West Haven, United StatesContact added •••5711Contact added (no phone or email listed)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Active, not recruiting→Recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40484114 ↗
    Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine is now Recruiting
    Primary completion Jul 1, 2026→Jul 1, 2030
    Study completion Dec 1, 2026→Dec 1, 2030
    Enrollment 30→10
    Contact Study contact now listed: added h•••@yale.edu · •••5711. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine · West Haven, United StatesContact added •••5711Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04711915
Lead sponsor
Yale University
Responsible party
Deepak C. D'Souza (Professor of Psychiatry, Yale University) — Principal investigator
First posted
Jan 15, 2021
Start date
Mar 17, 2021
Primary completion
Jul 1, 2030 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Hamideh Safi-Aghdam, MD
Contact
hamideh.safi-aghdam@yale.edu
203-932-5711 ext. 4650

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion